Abstract
Lung infections may be bacterial, viral or fungal and they are typically treated with oral or parenteral antibiotics. Inhaled dry powder formulations offer unique opportunities for treating lung infections with enhanced effectiveness and stability. Since drug delivery to the lungs requires chronic and repeated administration of larger amounts of therapeutics, dry powder formulations are attractive alternatives to deliver drugs directly to the lungs as they are not limited by solubility issues and they are regarded as being more stable than liquid dosage forms. This state-of-the-art review presents the use of inhaled formulations for tuberculosis as a main focus, but also for other diseases such as bronchiectasis, chronic obstructive pulmonary disease (COPD), pneumonia and respiratory infections occurring as complications during lung transplants. Opportunities for the use of inhaled therapies and other respiratory diseases or as prevention or antidotes against warfare agents are offered. Typical and novel inhaled formulations that have been used as well as preclinical and clinical studies and evaluation of these inhaled therapies are discussed for each disease state. Lastly, the use of inhaled therapies as an alternative to end the emergence of drug resistant strains is discussed along with the risks of increasing these resistant strains if the inhaled therapy is not designed based on dosing regimens established by wellplanned pharmacokinetic and pharmacodynamic studies.
Keywords: Tuberculosis, dry powder inhalers, antibiotics, pneumonia.
Current Pharmaceutical Design
Title:Inhaled Formulation Design for the Treatment of Lung Infections
Volume: 21 Issue: 27
Author(s): Lucila Garcia-Contreras and Khushwant S. Yadav
Affiliation:
Keywords: Tuberculosis, dry powder inhalers, antibiotics, pneumonia.
Abstract: Lung infections may be bacterial, viral or fungal and they are typically treated with oral or parenteral antibiotics. Inhaled dry powder formulations offer unique opportunities for treating lung infections with enhanced effectiveness and stability. Since drug delivery to the lungs requires chronic and repeated administration of larger amounts of therapeutics, dry powder formulations are attractive alternatives to deliver drugs directly to the lungs as they are not limited by solubility issues and they are regarded as being more stable than liquid dosage forms. This state-of-the-art review presents the use of inhaled formulations for tuberculosis as a main focus, but also for other diseases such as bronchiectasis, chronic obstructive pulmonary disease (COPD), pneumonia and respiratory infections occurring as complications during lung transplants. Opportunities for the use of inhaled therapies and other respiratory diseases or as prevention or antidotes against warfare agents are offered. Typical and novel inhaled formulations that have been used as well as preclinical and clinical studies and evaluation of these inhaled therapies are discussed for each disease state. Lastly, the use of inhaled therapies as an alternative to end the emergence of drug resistant strains is discussed along with the risks of increasing these resistant strains if the inhaled therapy is not designed based on dosing regimens established by wellplanned pharmacokinetic and pharmacodynamic studies.
Export Options
About this article
Cite this article as:
Garcia-Contreras Lucila and Yadav S. Khushwant, Inhaled Formulation Design for the Treatment of Lung Infections, Current Pharmaceutical Design 2015; 21 (27) . https://dx.doi.org/10.2174/1381612821666150820110305
DOI https://dx.doi.org/10.2174/1381612821666150820110305 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design HIV Vaccines: A Global Perspective
Current Molecular Medicine A Glance on the Role of Bacterial Siderophore from the Perspectives of Medical and Biotechnological Approaches
Current Drug Targets Mechanism of Action: How Nano-Antimicrobials Act?
Current Drug Targets Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Smart Phones As a Viable Data Collection Tool in Low-resource Settings: Case Study of Rwandan Community Health Workers
Neuroscience and Biomedical Engineering (Discontinued) miR-202 Mediates Metabolic Shift in Lung Cancer Cells via Targeting HK2
Current Signal Transduction Therapy Subtracting Gene Function by Gene Silencing and Disruption in Bacteria
Current Biotechnology Biomarker Discovery in Clinical Proteomics: Strategies for Exposing Low Abundant Proteins
Current Proteomics Tuberculostatic Drugs Targeting Infections of the Central Nervous System
Anti-Infective Agents Intraocular Immune Mechanisms in Uveitis
Current Immunology Reviews (Discontinued) Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry Epidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Current Drug Targets Serum and Bronchoalveolar Lavage Fluid 25(OH)Vitamin D3 Levels in HIV-1 and Tuberculosis: A Cross-Sectional Study from a Tertiary Care Center in North India
Current HIV Research Primary Isolated Mediastinal Abscess Masquerading as Mediastinal Mass- A Needle did the Trick
Current Respiratory Medicine Reviews Exploring Novel Target Space: A Need to Partner High Throughput Docking and Ligand-Based Similarity Searches?
Combinatorial Chemistry & High Throughput Screening Review of Pediatric Uveitis
Current Pediatric Reviews New Quinolinyl–1,3,4–Oxadiazoles: Synthesis, In Vitro Antibacterial, Antifungal and Antituberculosis Studies
Medicinal Chemistry Cytoplasmic and Nuclear Accumulation of Antisense Oligomers Incubated as Streptavidin Delivery Nanoparticles
Current Radiopharmaceuticals Bacterial Resistance to Antimicrobial Host Defenses - An Emerging Target for Novel Antiinfective Strategies?
Current Drug Targets